DiaMedica Therapeutics, Inc.
B-1250 Waverley Street
Winnipeg
Manitoba
R3T 6C6
Canada
Tel: 204-487-3806
Fax: 204-453-3745
Website: http://www.diamedica.com/
Email: info@diamedica.com
118 articles about DiaMedica Therapeutics, Inc.
-
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
4/28/2022
DiaMedica Therapeutics Inc. today announced that its first quarter 2022 financial results will be released after the markets close on Wednesday, May 4th.
-
DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022
3/8/2022
DiaMedica Therapeutics Inc. today announced that its fourth quarter 2021 financial results will be released after the markets close on Monday, March 14th .
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
2/2/2022
DiaMedica Therapeutics Inc. announced today the appointment of Dominic Cundari as Chief Commercial Officer.
-
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
1/5/2022
DiaMedica Therapeutics Inc. announced today the appointment of Kirsten Gruis, M.D. as Chief Medical Officer.
-
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/17/2021
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
11/10/2021
DiaMedica Therapeutics Inc. today provided a business update and financial results for the quarter ended September 30, 2021. Management will host a conference call Thursday, November 11, 2021, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and third quarter financial results.
-
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
11/8/2021
DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted and concluded that DiaMedica “may proceed” with the proposed clinical investigation using its amended protocol adding stroke recurrence as a second independent primary endpoint to its Phase 2/3 ReMEDy2 trial
-
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
11/4/2021
DiaMedica Therapeutics Inc. today announced that its third quarter 2021 financial results will be released after the markets close on Wednesday, November 10th.
-
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
8/11/2021
DiaMedica Therapeutics Inc. today provided a business update and financial results for the quarter ended June 30, 2021. DiaMedica will host a conference call Thursday, August 12, 2021, at 7:00AM Central Time/8:00AM Eastern Time to discuss its business update and second quarter financial results.
-
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
8/5/2021
DiaMedica Therapeutics Inc. today announced that its second quarter 2021 financial results will be released after the markets close on Wednesday, August 11 th .
-
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke
5/17/2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical Company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application.
-
DiaMedica Therapeutics Announces 2020 Financial Results and Provides a Business Update
3/10/2021
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, provided a business update and financial results for the year ended December 31, 2020.
-
DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference
1/11/2021
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.
-
DiaMedica Therapeutics Announces Successful Type B Meeting with FDA for the Study of DM199 in Patients with Acute Ischemic Stroke
12/10/2020
DiaMedica Plans to Submit an Investigational New Drug (IND) Application with to FDA for a Phase 2/3 Study in the First Quarter of 2021
-
DiaMedica Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/19/2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders, is pleased to announce that Rick Pauls, President and CEO of DiaMedica, will participate in a fireside chat and host one-on-one meetings with invest
-
DiaMedica Therapeutics to Present at Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
9/15/2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4 th Annual Best Ideas Growth (BIG4) Conference, being held on Thursday, September 17, 2020, on a virtual platform. DiaMedica Therapeutics management is scheduled to meet with investor
-
DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results
5/13/2020
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, announced positive top-line results from ReMEDy, its Phase II study in acute ischemic stroke, as well as provided a business update and financial results for the three months ended March 31, 2020.
-
DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
5/13/2020
Company to discuss top-line data during its scheduled first quarter financial results conference call tomorrow at 8:00 am Eastern Time
-
DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference
3/26/2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled “Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease” at the National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference. For information about the virtual event, visit: